Is IonQ Stock a Buy for 2027?
IonQ's revenue is growing quickly, but the company is still a long way from profitability.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
